Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2001

View Archived Issues

Baxter expands capacity for plasma-based therapies

Aastrom Biosciences and the Karmanos Cancer Institute create new cell therapy center

OraSure Technologies files for approval of rapid HIV test

Synsorb Biotech receives milestone payment from MDS Proteomics

Potent and selective NCX inhibitor attenuates reperfusion injury following cerebral ischemia

EGIS-7229 moves into clinical development

Marked, long-lasting neuroprotection obtained after i.v. injection of BBB-targeting BDNF conjugate

Safety of vaccination with ALVAC vector-expressed p53 in primates

Rubitecan demonstrates potential in HIV therapy

NeoOncoRx completes acquisition of Neoquin; phase II trials to commence in U.K.

Nasal immunization of mice with an RSV subunit vaccine protects against viral challenge

SciClone's lead ISE approved for cancer indication in the Philippines

FDA Oncologic Drugs Advisory Committee to review Zevalin at upcoming meeting

Novel inhibitor of cPLA2 with topical and oral antiinflammatory activity

Hemolink advances through Canadian approval process

Shire highlights Q2 developments

Patient enrollment completed in phase I trial of Inex's INX-3280

Vion's Triapine enters phase II for treatment of leukemia

Patient enrollment completed in SafeScience phase II pancreatic cancer trial

VEGF inhibitors useful for angiogenesis-related disorders according to Yamanouchi

Antibacterial platinum complexes discovered at Asahi Kasei

Dual 5-HT reuptake inhibitors and 5-HT1A agonists reported by Sumitomo in recent patent

Sankyo reveals naturally produced MPO inhibitors

Hydroxamic acid derivatives useful as antimicrobials

Novel Genzyme intracellular delivery compounds particularly useful in gene therapy

Neuroprotective agents designed at Nippon Kayaku attenuate paclitaxel-induced damage